Newron Pharmaceuticals S.p.A. (NP5.DE)

EUR 8.8

(-0.34%)

Long Term Debt Summary of Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.'s latest annual long term debt in 2023 was 25.76 Million EUR , down -43.36% from previous year.
Newron Pharmaceuticals S.p.A.'s latest quarterly long term debt in 2024 Q2 was 48.53 Million EUR , down 0.0% from previous quarter.
Newron Pharmaceuticals S.p.A. reported annual long term debt of 45.49 Million EUR in 2022, up 5.96% from previous year.
Newron Pharmaceuticals S.p.A. reported annual long term debt of 42.93 Million EUR in 2021, up 63.9% from previous year.
Newron Pharmaceuticals S.p.A. reported quarterly long term debt of 25.76 Million EUR for 2023 FY, down -43.36% from previous quarter.
Newron Pharmaceuticals S.p.A. reported quarterly long term debt of 34.49 Million EUR for 2023 Q2, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Newron Pharmaceuticals S.p.A. (2023 - 2005)

Historical Annual Long Term Debt of Newron Pharmaceuticals S.p.A. (2023 - 2005)

Year	Long Term Debt	Long Term Debt Growth
2023	25.76 Million EUR	-43.36%
2022	45.49 Million EUR	5.96%
2021	42.93 Million EUR	63.9%
2020	26.19 Million EUR	55.67%
2019	16.82 Million EUR	13361.6%
2018	125 Thousand EUR	0.0%
2017	- EUR	0.0%
2016	- EUR	-100.0%
2015	364 Thousand EUR	-50.07%
2014	729 Thousand EUR	-32.93%
2013	1.08 Million EUR	-24.88%
2012	1.44 Million EUR	-19.7%
2011	1.8 Million EUR	0.0%
2010	- EUR	100.0%
2009	-2.65 Million EUR	-1039.22%
2008	283 Thousand EUR	-49.55%
2007	561 Thousand EUR	-32.65%
2006	833 Thousand EUR	-19.67%
2005	1.03 Million EUR	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q2	48.53 Million EUR	0.0%
2023 FY	25.76 Million EUR	-43.36%
2023 Q2	34.49 Million EUR	0.0%
2023 Q4	25.76 Million EUR	0.0%
2022 FY	45.49 Million EUR	5.96%
2022 Q4	45.49 Million EUR	0.0%
2022 Q2	44.29 Million EUR	0.0%
2021 FY	42.93 Million EUR	63.9%
2021 Q2	26.82 Million EUR	0.0%
2021 Q4	42.93 Million EUR	0.0%
2020 Q4	26.19 Million EUR	0.0%
2020 FY	26.19 Million EUR	55.67%
2020 Q2	25.27 Million EUR	0.0%
2019 Q4	16.82 Million EUR	0.0%
2019 FY	16.82 Million EUR	13361.6%
2019 Q2	9.4 Million EUR	0.0%
2018 FY	125 Thousand EUR	0.0%
2018 Q4	125 Thousand EUR	0.0%
2018 Q2	- EUR	0.0%
2017 Q2	- EUR	0.0%
2017 Q4	- EUR	0.0%
2017 FY	- EUR	0.0%
2016 Q4	- EUR	0.0%
2016 FY	- EUR	-100.0%
2016 Q2	182 Thousand EUR	0.0%
2015 Q4	364 Thousand EUR	0.0%
2015 FY	364 Thousand EUR	-50.07%
2015 Q2	549 Thousand EUR	0.0%
2014 FY	729 Thousand EUR	-32.93%
2014 Q4	729 Thousand EUR	0.0%
2014 Q2	907 Thousand EUR	0.0%
2013 Q4	1.08 Million EUR	0.0%
2013 FY	1.08 Million EUR	-24.88%
2013 Q2	1.26 Million EUR	0.0%
2012 FY	1.44 Million EUR	-19.7%
2012 Q4	1.44 Million EUR	0.0%
2012 Q2	1.62 Million EUR	0.0%
2011 Q2	1.98 Million EUR	0.0%
2011 FY	1.8 Million EUR	0.0%
2011 Q4	1.8 Million EUR	0.0%
2010 Q4	- EUR	0.0%
2010 FY	- EUR	100.0%
2010 Q2	-2.77 Million EUR	0.0%
2009 FY	-2.65 Million EUR	-1039.22%
2009 Q4	-2.65 Million EUR	0.0%
2008 FY	283 Thousand EUR	-49.55%
2007 FY	561 Thousand EUR	-32.65%
2006 FY	833 Thousand EUR	-19.67%
2005 FY	1.03 Million EUR	0.0%

Peer Long Term Debt Comparison of Newron Pharmaceuticals S.p.A.

Name	Long Term Debt	Long Term Debt Difference
Redcare Pharmacy NV	236.04 Million EUR	89.084%